Clene Inc Sustainability Reports
Clene Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of clean-surfaced nanotechnology therapeutics. Its lead drug candidate is an orally administered nanocrystal suspension engineered to treat neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00X3GTK84
2 reports from 2021 to 2023
Company Profile
Clene Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of clean-surfaced nanotechnology therapeutics. Its lead drug candidate is an orally administered nanocrystal suspension engineered to treat neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
